Catabasis Pharma (CATB) Surges 50% on Deal with Serepta (SRPT)
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Catabasis Pharma (NASDAQ: CATB) is surging 49% in early trade after the company announced a joint research collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy (DMD) with Serepta Therapeutics, Inc. (Nasdaq: SRPT).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA Advises Patients With St. Jude Medical (STJ) Heart Implants to Continue Using Devices - Reuters
- Aduro Biotech (ADRO) Announces Partial Clinical Hold of LADD Trials
- ARIAD Pharma (ARIA) volatility continues to move higher as shares trend lower
Create E-mail Alert Related CategoriesFDA, Momentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!